Hormonal Therapy News and Research

RSS

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Biomarkers can predict treatment response in women with endometriosis

Biomarkers can predict whether women will respond to the first-line treatment for endometriosis, an extremely painful condition in which the tissue usually found inside the uterus grows in places it shouldn't, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

24 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Breast cancer survival could be extended with two new drug combinations

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

21 Oct 2018

Radiotherapy can prolong survival in prostate cancer

A new major study from London has shown that radiotherapy can extend survival among patients with prostate cancer. The study shows that larger number of patients given standard therapy along with radiation therapy survived three years after the initiation of the study despite having a local spread of their cancer.

21 Oct 2018

High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients

Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018.

19 Oct 2018

Study reinvestigates benefit of biomarker tests in certain breast cancer patients

The German Institute for Quality and Efficiency in Health Care reinvestigated the benefit of biomarker tests to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, that is, women with primary hormone receptor-positive, HER2/neu-negative breast cancer and 0 to 3 affected lymph nodes.

7 Sep 2018

Chemotherapy may provide no benefit for breast cancer in some cases

In a new study a team of researchers have found that chemotherapy can be completely skipped in early stage breast cancer patients provided certain genetic tests of the tumours are made to assess the risk.

5 Jun 2018

African-American men with prostate cancer show stronger response to hormone therapy

African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study led by Duke Cancer Institute researchers.

4 Jun 2018

Prostate cancer on the rise and detected late in the UK finds report

As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.

9 Apr 2018

Multimodal treatment approach enhances long-term survival in men with metastatic prostate cancer

UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.

5 Mar 2018

Myriad's EndoPredict offers better prediction of breast cancer recurrence, analysis shows

Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.

19 Feb 2018

New clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy

An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics.

1 Feb 2018

Rutgers researcher receives $1 million grant for international prostate cancer study

A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia.

2 Jan 2018

Study finds new marker to detect fatal breast cancer

A new study conducted at the University College London, UK, found a new marker that has the capacity to help diagnose fatal breast cancer up to one year earlier than existing methods.

22 Dec 2017

Myriad Genetics announces new data on EndoPredict test at 2017 San Antonio Breast Cancer Symposium

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.

12 Dec 2017

Factors associated with disparities in breast cancer survival studied

According to a latest study, several factors are responsible for the differences in the survival statistics of the non-elderly women with breast cancer. For example in 2012, the health reports had revealed that black women have a 43% higher risk of death when affected with breast cancer compared to their white counterparts.

16 Oct 2017